SANGAMO THERAPEUTICS INC's ticker is SGMO and the CUSIP is 800677106. A total of 134 filers reported holding SANGAMO THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 1.23 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $171,691 | -54.3% | 286,247 | -0.8% | 0.00% | – |
| Q2 2023 | $375,300 | -13.9% | 288,692 | +16.6% | 0.00% | – |
| Q1 2023 | $435,886 | +14.9% | 247,662 | +105.0% | 0.00% | – |
| Q4 2022 | $379,346 | -37.2% | 120,811 | -1.9% | 0.00% | – |
| Q3 2022 | $604,000 | +21.5% | 123,120 | +2.5% | 0.00% | – |
| Q2 2022 | $497,000 | -28.4% | 120,067 | +0.5% | 0.00% | – |
| Q1 2022 | $694,000 | +13.8% | 119,415 | +46.8% | 0.00% | – |
| Q4 2021 | $610,000 | -77.8% | 81,327 | -73.3% | 0.00% | – |
| Q3 2021 | $2,742,000 | -36.5% | 304,350 | -15.6% | 0.00% | – |
| Q2 2021 | $4,318,000 | -31.5% | 360,728 | -28.3% | 0.00% | -100.0% |
| Q1 2021 | $6,304,000 | +8.1% | 503,127 | +34.7% | 0.00% | 0.0% |
| Q4 2020 | $5,830,000 | -19.0% | 373,627 | -51.0% | 0.00% | 0.0% |
| Q3 2020 | $7,199,000 | -3.0% | 761,827 | -8.0% | 0.00% | 0.0% |
| Q2 2020 | $7,423,000 | +40.7% | 828,427 | +0.0% | 0.00% | 0.0% |
| Q1 2020 | $5,275,000 | -68.8% | 828,127 | -59.0% | 0.00% | -50.0% |
| Q4 2019 | $16,919,000 | -23.5% | 2,021,327 | -17.3% | 0.00% | -33.3% |
| Q3 2019 | $22,114,000 | -23.4% | 2,443,550 | -8.8% | 0.00% | 0.0% |
| Q2 2019 | $28,857,000 | +23.7% | 2,679,450 | +9.6% | 0.00% | 0.0% |
| Q1 2019 | $23,323,000 | -17.5% | 2,444,750 | -0.7% | 0.00% | -25.0% |
| Q4 2018 | $28,254,000 | -37.2% | 2,461,150 | -7.3% | 0.00% | -20.0% |
| Q3 2018 | $45,020,000 | -4.5% | 2,656,105 | -20.0% | 0.01% | 0.0% |
| Q2 2018 | $47,131,000 | -41.7% | 3,319,050 | -21.9% | 0.01% | -50.0% |
| Q1 2018 | $80,778,000 | -8.0% | 4,251,459 | -20.6% | 0.01% | 0.0% |
| Q4 2017 | $87,829,000 | +105.9% | 5,355,421 | +88.3% | 0.01% | +100.0% |
| Q3 2017 | $42,658,000 | +200.9% | 2,843,889 | +76.5% | 0.01% | +150.0% |
| Q2 2017 | $14,178,000 | +69.2% | 1,611,083 | 0.0% | 0.00% | +100.0% |
| Q1 2017 | $8,378,000 | +61.2% | 1,611,083 | -5.4% | 0.00% | 0.0% |
| Q4 2016 | $5,197,000 | -34.1% | 1,703,783 | 0.0% | 0.00% | 0.0% |
| Q3 2016 | $7,889,000 | -55.0% | 1,703,783 | -43.8% | 0.00% | -50.0% |
| Q2 2016 | $17,542,000 | -4.3% | 3,029,683 | 0.0% | 0.00% | -33.3% |
| Q1 2016 | $18,330,000 | -52.6% | 3,029,683 | -28.5% | 0.00% | -40.0% |
| Q4 2015 | $38,709,000 | +52.9% | 4,239,783 | -5.6% | 0.01% | +25.0% |
| Q3 2015 | $25,322,000 | -46.5% | 4,489,783 | +5.2% | 0.00% | -33.3% |
| Q2 2015 | $47,352,000 | -28.4% | 4,269,815 | +1.2% | 0.01% | -25.0% |
| Q1 2015 | $66,180,000 | +6.1% | 4,220,681 | +2.9% | 0.01% | 0.0% |
| Q4 2014 | $62,361,000 | -5.6% | 4,099,975 | -33.0% | 0.01% | -11.1% |
| Q3 2014 | $66,034,000 | -29.4% | 6,122,775 | 0.0% | 0.01% | -30.8% |
| Q2 2014 | $93,495,000 | -15.5% | 6,122,775 | 0.0% | 0.01% | -13.3% |
| Q1 2014 | $110,700,000 | +85.1% | 6,122,775 | +42.2% | 0.02% | +87.5% |
| Q4 2013 | $59,805,000 | +52.8% | 4,305,600 | +15.3% | 0.01% | +33.3% |
| Q3 2013 | $39,133,000 | +144.5% | 3,734,100 | +82.2% | 0.01% | +100.0% |
| Q2 2013 | $16,003,000 | – | 2,049,100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 6,000,000 | $66,540,000 | 6.69% |
| FIC CAPITAL INC | 787,529 | $8,734,000 | 3.47% |
| RA Capital Management | 1,220,209 | $13,532,000 | 1.36% |
| PRINCETON CAPITAL MANAGEMENT INC | 114,120 | $1,266,000 | 0.67% |
| Perceptive Advisors | 800,000 | $8,872,000 | 0.53% |
| Cormorant Asset Management, LP | 361,000 | $4,003,000 | 0.53% |
| Highlander Capital Management, LLC | 43,500 | $482,000 | 0.43% |
| APEX CAPITAL, LLC | 439,900 | $4,878,000 | 0.42% |
| WASATCH ADVISORS LP | 3,091,386 | $34,283,000 | 0.37% |
| Baker Brothers Advisors | 3,230,932 | $35,831,000 | 0.31% |